Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation.

about

Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation.

Item

http://www.wikidata.org/entity/Q49563307

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Detecting clinically relevant ...... ents with atrial fibrillation.

@en

Detecting clinically relevant ...... ents with atrial fibrillation.

@nl

type

Item

label

Detecting clinically relevant ...... ents with atrial fibrillation.

@en

Detecting clinically relevant ...... ents with atrial fibrillation.

@nl

prefLabel

Detecting clinically relevant ...... ents with atrial fibrillation.

@en

Detecting clinically relevant ...... ents with atrial fibrillation.

@nl

P1476

Detecting clinically relevant ...... ients with atrial fibrillation

@en

P2093

Arina Ten Cate-Hoek

http://www.w3.org/2001/XMLSchema#string

Harry J Crijns

http://www.w3.org/2001/XMLSchema#string

Henri Spronk

http://www.w3.org/2001/XMLSchema#string

Hugo Ten Cate

http://www.w3.org/2001/XMLSchema#string

Paul Verhezen

http://www.w3.org/2001/XMLSchema#string

René van Oerle

http://www.w3.org/2001/XMLSchema#string

Rick Wetzels

http://www.w3.org/2001/XMLSchema#string

Simon Schalla

http://www.w3.org/2001/XMLSchema#string

Yvonne M C Henskens

http://www.w3.org/2001/XMLSchema#string

P2860

Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future : Views from a workshop at the European Medicines Agency (EMA)

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.

Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants.

Coagulation assays and anticoagulant monitoring.

New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.

Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.

Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.

Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.

P2888

s12959-017-0160-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12959-017-0160-2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anouk J W Gulpen

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100433804

http://www.w3.org/2001/XMLSchema#string

P698

29434525

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

5793444

http://www.w3.org/2001/XMLSchema#string